Form 4: Cytek Biosciences CEO Wenbin Jiang Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Wenbin Jiang, CEO of Cytek Biosciences, reports the acquisition of stock options and restricted stock units.
Summary
- On March 4, 2025, Wenbin Jiang, the President and CEO of Cytek Biosciences, was granted employee stock options for 735,294 shares of common stock at an exercise price of $4.31.
- These options vest over four years, starting April 4, 2025, with 1/48th of the shares vesting monthly.
- Jiang also received 464,037 restricted stock units (RSUs), each representing a contingent right to receive one share of Cytek's common stock.
- These RSUs vest over four years, with portions vesting on May 18, August 18, November 18, and March 10 of each year, starting in 2025 and 2026 respectively.
- Following these transactions, Jiang directly owns 735,294 derivative securities in the form of employee stock options and 464,037 derivative securities in the form of restricted stock units.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no immediate negative implications.
Positives
- The granting of stock options and RSUs to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
- The vesting schedules of the options and RSUs encourage long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules suggest a long-term commitment from the CEO.
Industry Context
Stock options and RSUs are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. This grant is typical for a CEO of a company like Cytek Biosciences.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
- Companies like Illumina, Thermo Fisher Scientific, and Danaher also utilize similar equity-based compensation to incentivize their executives.
- The vesting schedules and amounts granted are generally in line with industry norms for companies of Cytek Biosciences' size and stage of development.
Stakeholder Impact
- Shareholders may view the grant of stock options and RSUs positively as it incentivizes the CEO to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of the transaction: Wenbin Jiang acquired stock options and restricted stock units. |
| 04/04/2025 | First vesting date for the stock options (1/48th of the total shares). |
| 05/18/2025 | First vesting date for a portion of the restricted stock units (2/48th of the total shares). |
| 08/18/2025 | Second vesting date for a portion of the restricted stock units (3/48th of the total shares). |
| 11/18/2025 | Third vesting date for a portion of the restricted stock units (3/48th of the total shares). |
| 03/06/2025 | Date of the Form 4 filing. |
| 03/10/2026 | Fourth vesting date for a portion of the restricted stock units (4/48th of the total shares). |
| 03/04/2035 | Expiration date of the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.